financetom
Business
financetom
/
Business
/
Trump Media slides as lock-up expires
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trump Media slides as lock-up expires
Sep 22, 2024 9:16 AM

(Reuters) - Shares of Trump Media & Technology Group ( DJT ) fell 4.5% in premarket trading on Friday as the Truth Social parent extended this week's steep selloff after a lock-up on insider sales expired.

Shares of the $2.9 billion firm, which is 57% owned by U.S. Republican candidate Donald Trump, have slumped about 18% in the past four straight sessions and is down about 80% from their April peak.

Trump, whose stake is currently worth $1.6 billion, said last week he does not plan on selling his shares, turning the focus to other major stakeholders who could sell shares.

United Atlantic Ventures and Patrick Orlando, whose fund, ARC Global Investments II, sponsored the blank-check company that merged with Trump Media ( DJT ) in March, together own about 11% of Trump Media ( DJT ) shares.

With only a third of Trump Media's ( DJT ) shares currently available for trading, any stake sale is expected to rock the shares.

"Not only will the possible new selling activity affect DJT's stock price directly, it will also increase DJT's stock lending pool which will facilitate increased short selling in the stock," said Ihor Dusaniwsky, managing director of predictive analytics at S3 Partners, in a note on Thursday.

Trump Media ( DJT ) and Orlando did not immediately respond to a request for a comment.

The loss-making company was last trading at $13.94 as restrictions on insider sales expired Thursday after markets closed.

(Reporting by Medha Singh in Bengaluru; Editing by Saumyadeb Chakrabarty)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FEATURE-Cradle of freedom? Saudis lambasted for hosting UN internet forum
FEATURE-Cradle of freedom? Saudis lambasted for hosting UN internet forum
Dec 17, 2024
* UN Internet Governance Forum in Riyadh draws criticism * Kingdom slammed for detaining rights activists * 'Reputation washing' picks up pace under grand MBS vision By Nazih Osseiran BEIRUT, Dec 17 (Thomson Reuters Foundation) - Saudi Arabia plays host this month to a major United Nations effort to discuss internet policy, drawing accusations of rank hypocrisy from rights activists...
Joby Aviation Completes Key Aerostructure Tests For FAA Certification
Joby Aviation Completes Key Aerostructure Tests For FAA Certification
Dec 17, 2024
Joby Aviation, Inc. ( JOBY ) is making significant strides in its journey toward FAA certification, as its shares rise in premarket trading following the announcement of a major achievement. The company has successfully completed a critical series of aerostructure tests for certification credit with the Federal Aviation Administration. The successful static load testing of Joby’s tail structure is a...
Sanofi and Teva's bowel disease drug meets main goals in mid-stage trial
Sanofi and Teva's bowel disease drug meets main goals in mid-stage trial
Dec 17, 2024
Dec 17 (Reuters) - Sanofi and Teva Pharmaceuticals said on Tuesday that their drug, duvakitug, met the main goals in a mid-stage trial when tested in patients with inflammatory bowel disease (IBD). The drug met the main goals of disease remission and effectiveness for the treatment of ulcerative colitis and Crohn's disease, respectively. These are the two most common forms...
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target
Dec 17, 2024
08:01 AM EST, 12/17/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday its phase 3 trial evaluating Eylea HD injection 8 mg in patients with macular edema following retinal vein occlusion met its primary endpoint. The study demonstrated that patients treated with Eylea HD every 8 weeks, following three or five initial monthly doses, achieved non-inferior vision gains...
Copyright 2023-2026 - www.financetom.com All Rights Reserved